Pliant Therapeutics Inc (NASDAQ:PLRX) announced positive data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The trial met its primary and secondary endpoints, demonstrating that bexotegrast was well tolerated and its plasma concentrations increased with dose. The trial's exploratory efficacy endpoints showed bexotegrast reduced both ELF scores and PRO-C3 levels at Week 12 at all doses relative to placebo. PLRX shares were up 13.10% at $16.48 on the last check Tuesday.